S328 clinicopathological parameters was tested by Chi-square test, two-sided Fisher's exact test, and Cox regression using SPSS version 12.0 and STATA version 7.0 software. Result: Overall, 36 amplicons, 3 homozygous deletions, and 17 minimally altered regions (MAR) common to many lung cancers were identified. Among them, genomic changes on 13q21, 1p32, Xq and Yp were found to be significantly associated with clinical features, such as age, stage, and disease recurrence. Kaplan-Meier survival analysis revealed that genomic changes on 10p, 16q, 9p, 13q, 6p21 and 19q13 were associated with poor survival. Multivariate analysis showed that alterations on 6p21, 7p, 9q, and 9p were remained as independent predictors for poor outcome. In addition, significant correlations were observed for 3 pairs of MARs (19q13 and 6p21, 19p13 and 19q13, and 8p12 and 8q11), which indicated their possible collaborative roles. We examined the expression level of ECT2, one of the genes located in the most recurrently gained region on 3q26 by real-time qPCR. Expression of ECT2 was generally appeared to be up-regulated in NSCLCs. Conclusion: These results show that the novel genomic alterations identified in this study along with their clinicopathological implications would be useful to elucidate molecular mechanisms of lung cancer and to identify reliable biomarkers for clinical application.
Integrative genomic and gene expression analysis of NSCLC identifies subtype-specific signatures of pathway disruption
Lockwood, William W. 1 Chari, Raj 1 Coe, Bradley P. 1 Buys, Timon P. 1 English, John C. 1 Yee, John 1 Tsao, Ming-Sound 2 MacAulay, Calum 1 Lam, Stephen 1 Lam, Wan L. 1 1 British Columbia Cancer Agency, Vancouver, BC, Canada 2 Ontario Cancer Institute/Princess Margaret Hospital, Toronto, ON, Canada Background: Lung cancer is a leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) accounts for ~85% of lung cancers, with squamous cell carcinoma (SqCC) and adenocarcinoma (AC) comprising the two main subtypes. SqCC typically develops in the central airways, and AC characteristically originates in the peripheral lung. Although these subtypes can be distinguished readily at the histological level, knowledge of the genetic mechanisms underlying their differences will lead to the development of novel disease specific therapeutic strategies. Previous studies suggest that distinct patterns of genomic alteration exist for AC and SqCC. However, the specific genes responsible for the different tumor phenotypes remain largely unknown. Initial gene expression profiling studies have yielded some insight into the tumor subtypes and are able to segregate tumors into histologic groupings based on multi-gene models. Since not all gene expression changes are causal to disease development, it is challenging to distinguish critical events from reactive changes through global gene expression profiles alone. Thus, an integrative approach is necessary to fully understand the causal genetic events and downstream effects on disease phenotype. Objective: To comprehensively identify the underlying molecular differences between SqCC and AC using an integrative genome and transcriptome analysis. The discovery of genes differentially altered in each phenotype may clarify mechanisms of tumor differentiation and identify novel molecular targets for early diagnosis and therapy Methods: A whole genome tiling path CGH array was used to generate copy number profiles of 103 AC and 58 SqCC tumors. This array allows the detection of small segmental alterations such as micro-am-plifications and focal deletion which may have been undetected by conventional cytogenetic methods. Array data was visualized using SeeGH software and subjected to a smoothing computational algorithm to determine chromosomal areas of gain and loss. The resulting frequencies of alteration for each locus were compared between AC and SqCC using Fisher's Exact Test and regions with difference of p<0.001 were considered statistically significant. This genomic data was then integrated with genome wide expression data to identify genes deregulated as a result of copy number alterations specific to each NSCLC subtype. Results: Subtype specific copy number changes were identified. Regions of alteration disparity were mapped to chromosomes arms 2p, 3q, 4p, 4q, 8p, 12p, 19p, 19q, 20p and 22q . Analysis of expression data for the genes in these regions identified 183 unique genes differentially expressed between the subtypes as a result of copy number changes. Clustering and principle component analysis confirmed that these gene signatures were able to accurately delineate the disease subtypes. Grouping of these genes by biological function showed that many important pathways are differentially altered in AC and SqCC in disease specific ways. Conclusions: Whole genome array CGH comparison between AC and SqCC tumor genomes identified tumor subtype-specific genetic alterations. Integration of gene expression data delineated genes and pathways that could be important in phenotype differentiation. Characterization of these genes is now underway with the aim of defining new molecular targets for early diagnosis and treatment.
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Cancer Background: Prevention of primary tumour development remains to be the foundation for lung cancer control. Chemoprevention is defined as a pharmacologic intervention to suppress or reverse the carcinogenic process, and effective chemoprevention agents for lung cancer are needed. Due to effective public health campaigns for tobacco control, many lung cancers now arise in former smokers. We hypothesise that genomic changes common to current and former smokers represent authentic, permanent molecular changes altered by tobacco-smoke and may therefore represent crucial aberrations that lead to tobacco-smoke related lung carcinogenesis. Hence, the identification of these causal smoking-related lung cancer genes represent drug-able targets for the development of novel or natural chemoprevention agents for the prevention of lung cancer in former smokers.
Methods:
We analysed a total of 84 fresh tumour tissues from resected primary non-small cell lung carcinomas (NSCLCs): 46 current smokers (still smoking or quit less than one year prior to surgical resection), 26 former smokers (quit more than ten years prior to surgical resection), and 12 never smokers (smoked less than 100 cigarettes in lifetime). All smokers had at least 20 pack-years smoking history. Patients were matched on age (±10 years) and tobacco-smoke exposure (±10 pack-years). There was no significant difference in sex, histology, age or tobacco-smoke exposure between smoking groups. High molecular weight tumour DNA was digested, fluorescently labelled and hybridised against female human genomic DNA to a high resolution array-Comparative Genomic Hybridisation (aCGH) platform containing ~43,000 probes (Agilent 44K Human Whole-Genome 44B arrays). Genomic regions with significant copy-number variation (CNV) (DNA gain/loss) were identified using an aberration detection algorithm (CGH Analytics V3.4).
Results:
The most frequent CNVs in current smokers were gain of 1q21.1-q24.2 and 5p15.33-p12 (>60% of tumours) and loss of 8p23.3-p12 and 13q12.11-q34 (>20% of tumours). The most frequent CNVs in former smokers were gain at 1q25.2-q44 and 17q11.2-q25.3 (>50% of tumours) and loss at 13q12.11-q21.2 and 21q11.2-q22.3 (>20% of tumours). The most frequent CNVs in never smokers were gain at 7p22.3-p11.2 (>50% of tumours) and loss at 8p23.3-p11.22 and 13q13.3-q14.3 (>50% of tumours). CNVs present in both current and former smokers were compared to identify recurrent (occurring in >30% of tumours, both smokers and former smokers) genomic aberrations. Frequent copy-number gain was observed at 1q21.1-q31.3, 1q31.1-q44, 3q26.1-q29, 5p15.33-p12, 7p22.1-p11.2, 7p11.1-q36.2, and 17q21.2-q25.3. Gain at 1q25.2-q31.3 occurred in more than 50% of current and former smokers, yet was rarely gained in never-smokers (8%).
Conclusions:
In the chaos that occurs in lung cancer cells that develop in current smokers (with continued carcinogenic exposure and therefore high lung cancer risk), those aberrations in common with lung cancer cells that develop in former smokers (with no further carcinogenic exposure and therefore lower but persistent lung cancer risk) may represent irreversible causative genetic damage. Genes located in these aberrations represent strong chemoprevention targets. Our analysis has identified several loci frequently aberrant in both current and former smokers. These loci are now being further studied to identify the potential gene targets of aberration. Funding: IASLC Lung Cancer Fellowship, NHMRC (338602, 338200), TPCH (FRC0205-23). Methods: From 2004 to 2006 4104 Danish smokers and previous smokers were randomized to either screening with annual low dose CT scans for 5 years or no screening. A history of cigarette smoking of at least 20 pack years was required. All had lung function tests, and questionnaires regarding psychosocial consequences of screening, smoking and smoking cessation at randomization and planned annually. All scans are performed with a 16 detector row CT scanner at low dose levels, and viewed independently by two board certified radiologists. Nodules identified in the baseline year were considered prevalence nodules. Nodules were classified according to size and other characteristic: • Nodules smaller than 5 mm and calcified nodules with a maximal diameter up to 20 mm were just tabulated. • Uncalcified nodules with a diameter between 5 and 15 mm were re-scanned after 3 months; 1) if the size was stable or reduced no further action was taken.2) If the nodule grew it was referred for invasive workup, as were uncalcified nodules larger than 15 mm. CT with contrast and PET CT was performed before any invasive procedures. Results: At baseline 177 persons had nodules larger than 5 mm on the first scan, and almost all were rescanned after 3 months.
• Seventeen individuals (0.8%) with a suspicious lung nodule were referred to surgical exploration and all turned out to have cancer. One stage IA patient had segmental resection (adenocarcinoma (ACL) dominated by BAC features), ten patients (6 stage IA, 3 stage IB and 1 stage IIIB) had lobectomy (9 ACL and 1 squamous cell carcinoma (SQC), one stage IIIA had pneumonectomy (ACL).The remaining five patients were in stage IIIA after diagnostic evaluation and received chemotherapy (3 non small cell lung carcer (NSCLC), probably ACL, 1 ACL, 1 SQC). • Seventy one percent had ACL, 12% SQC and 17% NSCLC. No SCLC was diagnosed. • Twelve of 17 lung cancers at base line were treated surgically, 8 of these were treated by VATS resection. • One participant had a benign hamartoma (4 cm) removed by VATS local resection and one had a diagnostic VATS on suspicion of mesothelioma which turned out to be pleural tuberculosis. • Rate of false positive diagnoses was 8,6 %. • In the control group so far one patient had a lobectomy (ACL) stage 1, one had a pneumonectomy for a stage IIIA lung cancer, two had oncological treatment for stage 4 disease (ACL) and one patient died with lung cancer stage IIIB (ACL). Conclusion: Screening facilitates minimal invasive treatment and can be performed with a low rate of false positive diagnoses.
